» Articles » PMID: 10448778

Long-term Use of Oral Anticoagulants and the Risk of Fracture

Overview
Journal Arch Intern Med
Specialty General Medicine
Date 1999 Aug 17
PMID 10448778
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Vitamin K participates in bone metabolism and, since oral anticoagulants antagonize vitamin K, their use may increase the risk of osteoporosis.

Objective: To evaluate fracture risk at all skeletal sites following exposure to oral anticoagulants.

Methods: In a population-based retrospective cohort study, 572 Olmsted County, Minnesota, women 35 years or older at their first lifetime venous thromboembolism event between 1966 and 1990 were followed up for fractures. Risk was assessed by comparing new fractures with the number expected from sex- and age-specific fracture incidence rates for the general population (standardized incidence ratio [SIR]).

Results: Altogether, 480 fractures occurred during 6314 person-years of follow-up. Increasing exposure to oral anticoagulation was associated with an increased SIR for vertebral fractures: at less than 3 months of exposure, 2.4 (95% confidence interval [CI], 1.6-3.4); 3 to less than 12 months, 3.6 (95% CI, 2.5-4.9); and 12 months or more, 5.3 (95% CI, 3.4-8.0); and for rib fractures: at less than 3 months, 1.6 (95% CI, 0.9-2.7); 3 to less than 12 months, 1.6 (95% CI, 0.9-2.6); and 12 months or more, 3.4 (95% CI, 1.8-5.7). The data revealed no increased risk for other types of fractures. Oral anticoagulation for 12 months or more was an independent predictor of vertebral fractures (P = .009) and rib fractures (P = .02), but not other fractures.

Conclusions: Long-term exposure to oral anticoagulation is associated with an increased risk of vertebral and rib fractures. The mechanism by which this occurs is still unclear and needs further investigation.

Citing Articles

An electronic health record (EHR)-based risk calculator can predict fractures comparably to FRAX: a proof-of-concept study.

Jain R, Polley E, Weiner M, Iwamaye A, Huang E, Vokes T Osteoporos Int. 2024; 35(12):2117-2126.

PMID: 39147872 DOI: 10.1007/s00198-024-07221-2.


Anticoagulant use in older persons at risk for falls: therapeutic dilemmas-a clinical review.

Mitchell A, Elmasry Y, van Poelgeest E, Welsh T Eur Geriatr Med. 2023; 14(4):683-696.

PMID: 37392359 PMC: 10447288. DOI: 10.1007/s41999-023-00811-z.


The interplay between bone and heart health as reflected in medication effects: A narrative review.

Trost S, Tesfaye N, Harindhanavudhi T Womens Health (Lond). 2023; 19:17455057231165549.

PMID: 37078403 PMC: 10126623. DOI: 10.1177/17455057231165549.


Drugs associated with incident fragility fractures in kidney transplant recipients.

Batteux B, Nowak A, Sejourne A, Penet C, Masmoudi K, Brazier F Clin Kidney J. 2023; 16(3):571-584.

PMID: 36865022 PMC: 9972841. DOI: 10.1093/ckj/sfac265.


Fracture in clinical studies of tofacitinib in rheumatoid arthritis.

Hansen K, Mortezavi M, Nagy E, Wang C, Connell C, Radi Z Ther Adv Musculoskelet Dis. 2023; 14:1759720X221142346.

PMID: 36601090 PMC: 9806361. DOI: 10.1177/1759720X221142346.